Covid-19 Ivermectin

Uporabnik johan_blond je napisal:

Problem je, da je ta pladenj precej ubog. Npr. tvoj zgornji prispevek o ivermectinu in molecular docking je vsebinsko totalno sranje (pa je mi je jasno da je to preprint, ki so ga eni nadebudni znanstveniki objavili).

Bi se dalo napisat cel esej, kjer bi lahko od črtice do črtice razložil, zakaj je arXiv preprint Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity and possible therapeutics zmazek (ampak je res škoda mojega časa).

Ti dam en izziv, koliko se spoznaš, a lahko (brez googla) streseš iz rokava slovenski prevod za molecular docking pa scoring function.

Klikni za razširitev

Uporabnik dejan_ je napisal:

Ne more, nima več, iverca skurila vse.

Pa kaj se sploh še bockate z bolnikom.
Meni je edino žal, da ga ne morem dati na ignore, ker je pač moderator. Vse ostale njegove somišljenike sem že pred časom poklikal na ignore

Klikni za razširitev

Is the Queen, like 200 members of the US Congress, secretly using Ivermectin to treat Covid?

Horse paste for your Queen?

twoplustwoequalsfournews.wordpress.com

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database​

Abstract: We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. We controlled for the following demographics, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use. We measured association with mortality as the primary outcome, with significance assessed at p<0.05.

Results: There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator support. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventilator support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)),Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.

Conclusion: Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.

Klikni za razširitev